[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione(suxibuzone), antiinflammatory drug. I. Plasma levels and urinary excretion after oral administration of suxibuzone (author's transl)].
D000284:Administration, Oral; D000818:Animals; D004285:Dogs; D005260:Female; D000882:Haplorhini; D066298:In Vitro Techniques; D008297:Male; D010653:Phenylbutazone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D013045:Species Specificity
C003371:suxibuzone; D010653:Phenylbutazone